Blood Journals Portfolio/LinkedIn
Sep 8, 2025, 03:48
Blood Podcast Alert: Voxelotor Drops, Pediatric SCD, Thrombosis in VEXAS Syndrome and TKIs in ALL
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia describes how voxelotor is raising hemoglobin.
Highlights are:
- Kids + sickle cell + voxelotor: Imagine your kid’s brain saying “thanks” while your hemoglobin goes up, up, up. Voxelotor drops cerebral blood flow and oxygen extraction to more normal levels—like a spa retreat for tiny brains in crisis.
- VEXAS syndrome, meet your match: Thrombosis stages its dramatic entrance—because immune dashboards love throwing plot twists.
- ABL-class ALL hitting back: Tyrosine kinase inhibitors show they still remember their moves—clocking responses like a perfect encore.
Listen to the full episode here.”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 07:11Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
-
Sep 8, 2025, 06:54Indraneel Deshmukh Presenting Posters on Polycytemia Vera and More at SOHO 2025
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 8, 2025, 06:19Maria Abbattista: From Combined Hormonal Contraceptives to Cerebral Vein Thrombosis
-
Sep 8, 2025, 06:12David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress
Sep 9, 2025, 05:53
Sep 9, 2025, 05:37